3 Healthcare Stocks That Have a Killer Advantage

In This Article:

Some stocks just have it. What is "it"? A killer advantage that makes them dominant in their industry.

Three healthcare stocks that definitely enjoy such an advantage are Illumina (NASDAQ: ILMN), Intuitive Surgical (NASDAQ: ISRG), and Teladoc Health (NYSE: TDOC). Here's what makes these stocks stand out from all the rest -- and why they're great long-term picks for investors to buy now.

Glowing drawing of person with arms raised with other human figures standing on a lower level.
Glowing drawing of person with arms raised with other human figures standing on a lower level.

Image source: Getty Images.

1. lllumina

When it comes to gene sequencing, no company has succeeded like Illumina has. The company's technology has enabled reducing the cost of sequencing a human genome from $20 million in 2006 to around $1,000 today. Over 90% of all gene sequencing performed to date was done using Illumina's systems.

There are other companies that sell gene-sequencing systems. But Illumina's large install base gives it a substantial competitive advantage. So does the company's continual innovation. Illumina expects its NovaSeq platform, launched last year, will eventually help lower the cost of sequencing a genome to $100 or less.

The tremendous cash flow generated from sales of its systems -- and, more importantly, consumables used in gene sequencing -- enables Illumina to keep plowing money back into more research and development. It also allows Illumina to make strategic acquisitions to stay on top. The company's recently announced buyout of Pacific Biosciences of California is a great example, as the deal will provide Illumina with a leading platform for long-read sequencing.

2. Intuitive Surgical

Intuitive Surgical pioneered the use of robotic assistance in performing minimally invasive surgeries. The company estimates that around 5 million surgeries have been performed using its da Vinci robotic surgical system since the first version of the system was cleared by the Food and Drug Administration in 2000.

There are a couple of key advantages that Intuitive Surgical claims as a result of its years of expertise in robotic surgery. One is that no rival can come close to the safety track record that Intuitive has with da Vinci. Companies with newer surgical robot systems have a lot more convincing to do to win new customers than Intuitive does. This gives Intuitive Surgical a strong moat to defend its market share.

Another big advantage for Intuitive Surgical is that its customers have a financial incentive to maximize their return on investment. This means that they perform more procedures with the da Vinci system. That's music to Intuitive's ears since the company can count on a recurring and growing revenue source from selling replacement instruments.